000164189 001__ 164189
000164189 005__ 20230915092429.0
000164189 0247_ $$2doi$$a10.1186/s42466-021-00106-3
000164189 0247_ $$2pmid$$apmid:33691803
000164189 0247_ $$2pmc$$apmc:PMC7944611
000164189 0247_ $$2altmetric$$aaltmetric:101678234
000164189 037__ $$aDZNE-2022-00845
000164189 041__ $$aEnglish
000164189 082__ $$a610
000164189 1001_ $$aMayer, Geert$$b0
000164189 245__ $$aInsomnia in neurological diseases.
000164189 260__ $$a[London]$$bBioMed Central$$c2021
000164189 3367_ $$2DRIVER$$aarticle
000164189 3367_ $$2DataCite$$aOutput Types/Journal article
000164189 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1655112980_6961
000164189 3367_ $$2BibTeX$$aARTICLE
000164189 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000164189 3367_ $$00$$2EndNote$$aJournal Article
000164189 500__ $$a(CC BY)
000164189 520__ $$aInsomnia is defined as difficulties of initiating and maintaining sleep, early awakening and poor subjective sleep quality despite adequate opportunity and circumstances for sleep with impairment of daytime performance. These components of insomnia - namely persistent sleep difficulties despite of adequate sleep opportunity resulting in daytime dysfunction - appear secondary or co-morbid to neurological diseases. Comorbid insomnia originates from neurodegenerative, inflammatory, traumatic or ischemic changes in sleep regulating brainstem and hypothalamic nuclei with consecutive changes of neurotransmitters. Symptoms of neurological disorders (i.e motor deficits), co-morbidities (i.e. pain, depression, anxiety) and some disease-specific pharmaceuticals may cause insomnia and/or other sleep problems.This guideline focuses on insomnias in headaches, neurodegenerative movement disorders, multiple sclerosis, traumatic brain injury, epilepsies, stroke, neuromuscular disease and dementia.The most important new recommendations are: Cognitive behavioral therapy (CBTi) is recommended to treat acute and chronic insomnia in headache patients. Insomnia is one of the most frequent sleep complaints in neurodegenerative movement disorders. Patients may benefit from CBTi, antidepressants (trazodone, doxepin), melatonin and gaba-agonists. Insomnia is a frequent precursor of MS symptoms by up to 10 years. CBTi is recommended in patients with MS, traumatic brain injury and. Melatonin may improve insomnia symptoms in children with epilepsies. Patients with insomnia after stroke can be treated with benzodiazepine receptor agonists and sedating antidepressants. For patients with dementia suffering from insomnia trazodone, light therapy and physical exercise are recommended.
000164189 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000164189 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000164189 650_7 $$2Other$$aClassifications
000164189 650_7 $$2Other$$aCognitive behavioral therapy
000164189 650_7 $$2Other$$aComorbid diseases
000164189 650_7 $$2Other$$aDiagnostic instruments
000164189 650_7 $$2Other$$aInsomnia
000164189 650_7 $$2Other$$aNeurological diseases
000164189 650_7 $$2Other$$aTherapeutic recommendations
000164189 7001_ $$aHappe, Svenja$$b1
000164189 7001_ $$aEvers, Stefan$$b2
000164189 7001_ $$0P:(DE-2719)2814194$$aHermann, Wiebke$$b3$$udzne
000164189 7001_ $$aJansen, Sabine$$b4
000164189 7001_ $$aKallweit, Ulf$$b5
000164189 7001_ $$aMuntean, Maria-Lucia$$b6
000164189 7001_ $$aPöhlau, Dieter$$b7
000164189 7001_ $$aRiemann, Dieter$$b8
000164189 7001_ $$aSaletu, Michael$$b9
000164189 7001_ $$aSchichl, Melanie$$b10
000164189 7001_ $$aSchmitt, Wolfgang J$$b11
000164189 7001_ $$aSixel-Döring, Friederike$$b12
000164189 7001_ $$aYoung, Peter$$b13
000164189 773__ $$0PERI:(DE-600)2947493-0$$a10.1186/s42466-021-00106-3$$gVol. 3, no. 1, p. 15$$n1$$p15$$tNeurological research and practice$$v3$$x2524-3489$$y2021
000164189 8564_ $$uhttps://pub.dzne.de/record/164189/files/DZNE-2022-00845.pdf$$yOpenAccess
000164189 8564_ $$uhttps://pub.dzne.de/record/164189/files/DZNE-2022-00845.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000164189 909CO $$ooai:pub.dzne.de:164189$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000164189 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2814194$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000164189 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000164189 9141_ $$y2021
000164189 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2020-09-08
000164189 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000164189 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-23
000164189 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2019-05-24T10:38:19Z
000164189 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2019-05-24T10:38:19Z
000164189 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2019-05-24T10:38:19Z
000164189 9201_ $$0I:(DE-2719)1510100$$kAG Teipel$$lClinical Dementia Research Rostock /Greifswald$$x0
000164189 980__ $$ajournal
000164189 980__ $$aVDB
000164189 980__ $$aUNRESTRICTED
000164189 980__ $$aI:(DE-2719)1510100
000164189 9801_ $$aFullTexts